BioSpace News Archive

The global ultrasonic scalpels market is envisaged to attain prominence in the coming years due to distinguishing advantages over electrosurgical equipment in terms of certain factors such as post-surgical operations and reduction of blood loss.

ANGLE plc a world-leading liquid biopsy company, announces that following a formal tender process, it has appointed PricewaterhouseCoopers LLP as its auditor for the Company and its subsidiaries for the financial year ended 31 December 2020.

Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment

Beactica Therapeutics AB, the Swedish drug discovery company, and University of Dundee, a top-ranked university in the UK for biological sciences, announced a new research collaboration agreement.

Latest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim’s position in the cancer vaccine and T-cell engager spaces

Paper published in Journal of Biological Chemistry demonstrates compatibility with downstream manufacturing technologies to help accelerate CAR-T or antibody therapeutics development

Opticyte Secures $4.6 Million in Funding to Develop First Cell O 2 Monitor for Reducing Organ Failure Opticyte obtains funding from a $2.9MM SBIR Phase IIB grant and completes a $1.7MM seed round to launch first observational trial of Opticyte Cell O 2 Monitor

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today an outline of its strategic priorities and action plan for 2021. The priorities for 2021 fall into four key areas: Near term focus on rare neurodegenerative diseases, especially ALS

ANANDA Scientific Inc., a biotech pharma company, and NYU Grossman School of Medicine today announced a new clinical trial evaluating the efficacy of cannabidiol in ANANDA’s proprietary delivery technology as a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms and Neurocognitive Impairment in patients with PTSD and with PTSD comorbid with traumatic brain injury. An Investigational New Drug (IND)

Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today highlights recent achievements and outlines expected key 2021 milestones at the J.P. Morgan 39 th Annual Healthcare Conference, held virtually. “2020 was a foundational year for A